OmniAb (OABI) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does OmniAb (OABI) do?
OmniAb Inc (OABI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Licenses transgenic animal platforms and screening software to biotechnology firms developing human antibody drugs. Licenses genetically engineered rodents and chickens to pharmaceutical companies for human antibody discovery. It is worth $733.68M on the market and sold $40.20M over the last year.
- Market cap
- $733.68M
- P/E ratio
- None (reported a loss)
- Annual sales
- $40.20M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind OABI
- OmniRat: Genetically engineered rat platform producing fully human antibodies, earning milestone and royalty payments from pharmaceutical partners.
- OmniChicken: Transgenic chicken platform designed to generate antibodies against human drug targets that mammalian systems cannot easily target.
- OmniMouse: Genetically modified mouse model that produces diverse human antibodies, earning access fees and downstream royalties from biotech licensees.
- OmniDeep: Computational and microfluidics screening platform that analyzes millions of single antibody-producing cells for biopharma clients.
OABI’s flags, in plain English
Each flag is a number from OmniAb’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 4.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 7% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Insiders Hold
Insiders own 18.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -108.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about OABI
How big is OmniAb?
OmniAb’s market cap is $733.68M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $40.20M: what customers paid the company over the last year, before any costs.
What is OABI’s P/E ratio?
OABI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with OABI?
Revenue depends heavily on the clinical trial success and development budgets of external pharmaceutical partners. That is one risk on OmniAb’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From OmniAb’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OABI’s filings on SEC.gov. The Margin Monkey is research, not advice.
